Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Minerva Neuroscie (NQ: NERV )

1.270 USD -0.030 (-2.31%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 22, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 245,850
Open 1.320
Bid (Size) 1.250 (15)
Ask (Size) 1.280 (1)
Prev. Close 1.300
Today's Range 1.250 - 1.320
52wk Range 1.250 - 4.115
Shares Outstanding 42,721,566
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Minerva Neurosciences Announces Study Results Demonstrating Bioequivalence of Phase 2b, Phase 3, and Planned Commercial Formulations of Roluperidone for Treatment of Negative Symptoms of Schizophrenia
Company to Request Pre-NDA Meeting with U.S. Food and Drug Administration 
From GlobeNewswire News Releases
Minerva Neurosciences Announces Appointment of Dr. Ramana Kuchibhatla as Senior Vice President and Head of Research & Development
Dr. Jay Saoud, Head of Research & Development, to retire from his current role and transition to an advisory role in which he will continue to support the preparation and planned submission of a New... 
From GlobeNewswire News Releases

Performance

YTD
-46.64%
-46.64%
1 Month
-37.75%
-37.75%
3 Month
-32.80%
-32.80%
6 Month
-49.80%
-49.80%
1 Year
-61.16%
-61.16%

More News

Read More
Minerva Neurosciences Reports Second Quarter 2021 Financial Results and Business Updates
From GlobeNewswire News Releases
Papyrus Therapeutics Inc. Announces Additions to Its Board of Directors
From Business Wire News Releases
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Tags EXAI Market News Benzinga
From Benzinga
15 Stocks Moving in Friday's Pre-Market Session
Tags IRNT Top Gainers Trading Ideas
From Benzinga
Minerva Posts Positive Bioequivalence Results For Schizophrenia Candidate Formulations
Tags News Phase 3 Trial General
From Benzinga
Analysts Forecast 70% Gains Ahead For LOPX
Tags ETFs
From ETF Channel
How The Parts Add Up: LOPX Targets $16
Tags ETFs
From ETF Channel
3 Downgraded Stocks to Sell in a Shaky Market
Tags Stocks / Equities Market News
From TalkMarkets
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
Tags LEGN GLPG ATXI
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.